Biofrontera Drug Patent Portfolio
Biofrontera owns 1 orange book drug protected by 4 US patents Given below is the list of Biofrontera's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12280146 | Nanoemulsion without propylene glycol | 08 Dec, 2043 | Active |
| US11235169 | Illumination device for photodynamic therapy, method for treating a skin disease and method for operating an illumination device | 15 Oct, 2040 | Active |
| US11540981 | Nanoemulsion formulation with improved stability and cell penetration | 07 Feb, 2028 | Active |
| US6559183 | Nano-emulsion of 5-aminolevulinic acid | 12 Nov, 2019 | Expired |
Latest Legal Activities on Biofrontera's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Biofrontera.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Mail O.P. Petition Decision | 21 Mar, 2024 | US11540981 |
|
Email Notification
Critical
| 21 Mar, 2024 | US11540981 |
| Mail-Petition Decision - Denied | 19 Mar, 2024 | US11540981 |
| Petition Decision - Denied | 18 Mar, 2024 | US11540981 |
| O.P. Petition Decision | 18 Mar, 2024 | US11540981 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 06 Dec, 2023 | US11540981 |
| Petition Entered | 27 Apr, 2023 | US11540981 |
|
Recordation of Patent Grant Mailed
Critical
| 03 Jan, 2023 | US11540981 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 03 Jan, 2023 | US11540981 |
|
Email Notification
Critical
| 15 Dec, 2022 | US11540981 |
|
Issue Notification Mailed
Critical
| 14 Dec, 2022 | US11540981 |
|
Application Is Considered Ready for Issue
Critical
| 02 Dec, 2022 | US11540981 |
| Dispatch to FDC | 02 Dec, 2022 | US11540981 |
|
Issue Fee Payment Verified
Critical
| 30 Nov, 2022 | US11540981 |
|
Issue Fee Payment Received
Critical
| 30 Nov, 2022 | US11540981 |
Biofrontera's Drug Patent Litigations
Biofrontera's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 16, 2026, against patent number US12280146. The petitioner Sun Pharmaceutical Industries, Inc., challenged the validity of this patent, with Biofrontera Inc. as the respondent. Click below to track the latest information on how companies are challenging Biofrontera's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US12280146 | January, 2026 | Pending | Biofrontera Inc. | Sun Pharmaceutical Industries, Inc. |
Biofrontera's Family Patents
Biofrontera Drug List
Given below is the complete list of Biofrontera's drugs and the patents protecting them.
1. Ameluz
Ameluz is protected by 4 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12280146 | Nanoemulsion without propylene glycol |
08 Dec, 2043
(17 years from now)
| Active |
| US11235169 | Illumination device for photodynamic therapy, method for treating a skin disease and method for operating an illumination device |
15 Oct, 2040
(14 years from now)
| Active |
| US11540981 | Nanoemulsion formulation with improved stability and cell penetration |
07 Feb, 2028
(1 year, 11 months from now)
| Active |
| US6559183 | Nano-emulsion of 5-aminolevulinic acid |
12 Nov, 2019
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ameluz's drug page